Wong Eugene Hung Chih, Liew Yew Toong, Loong Siow Ping, Prepageran Narayanan
Department of Surgery, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Sabah, Malaysia.
Otorhinolaryngology Department, University Malaya Medical Centre, Kuala Lumpur, Malaysia.
Ann Otol Rhinol Laryngol. 2020 Mar;129(3):287-293. doi: 10.1177/0003489419887410. Epub 2019 Nov 8.
Endoscopic endonasal nasopharyngectomy (EEN) for recurrent nasopharyngeal carcinoma (rNPC) is being increasingly used due to the added high magnification, reduced morbidities associated with open procedures and good survival outcomes. Most studies looked at usage of EEN in patients with lower recurrent staging (rT1 and rT2) although more and more surgeons are studying the outcome of EEN in advanced rNPC (rT3 and rT4). The aims of this study were to report the long-term 5-year survival outcome of EEN performed in patients with advanced rNPC, and to determine any prognostic factors for patients' survival.
All patients who underwent EEN for advanced rNPC between January 2003 and December 2015 inclusive were analyzed. All surgeries were performed in University Malaya Medical Centre in Kuala Lumpur and Queen Elizabeth Hospital in Sabah. We reported the 5-year overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS) and any related complications and significant prognostic factors.
Twelve patients with rNPC (2 rT3 and 10 rT4) were followed-up over a mean duration of 44.8 months (range, 40-440 weeks). The 5-year OS was 50.0% (mean 44.75 months), DFS was 25.0% (mean 35.25 months) and the DSS was 58.3% (mean 43.33 months). No severe operative complications were encountered and no independent prognostic factors for survival outcome were identified.
This is the first report in English that exclusively described the long-term 5-year survival data in patients with both rT3 and rT4 recurrent NPC after EEN. The data suggest that EEN is a feasible treatment to improve survival with minimal morbidities in patients with rT3 and rT4 recurrent NPC. However, more studies with larger patient size is recommended.
内镜鼻内鼻咽癌切除术(EEN)用于复发性鼻咽癌(rNPC)的情况日益增多,这是因为其具有更高的放大倍数、与开放手术相比发病率降低以及良好的生存结果。大多数研究关注的是EEN在复发分期较低(rT1和rT2)患者中的应用,尽管越来越多的外科医生正在研究EEN在晚期rNPC(rT3和rT4)中的治疗结果。本研究的目的是报告对晚期rNPC患者进行EEN后的5年长期生存结果,并确定患者生存的任何预后因素。
对2003年1月至2015年12月期间接受EEN治疗晚期rNPC的所有患者进行分析。所有手术均在吉隆坡的马来亚大学医学中心和沙巴的伊丽莎白女王医院进行。我们报告了5年总生存率(OS)、无病生存率(DFS)和疾病特异性生存率(DSS)以及任何相关并发症和重要预后因素。
12例rNPC患者(2例rT3和10例rT4)接受了平均44.8个月(范围40 - 440周)的随访。5年OS为50.0%(平均44.75个月),DFS为25.0%(平均35.25个月),DSS为58.3%(平均43.33个月)。未遇到严重手术并发症,也未确定生存结果的独立预后因素。
这是首篇用英文专门描述rT3和rT4复发性NPC患者接受EEN后5年长期生存数据的报告。数据表明,EEN是一种可行的治疗方法,可提高rT3和rT4复发性NPC患者的生存率,且发病率最低。然而,建议开展更多纳入更大样本量患者的研究。